Testing the theory of immune selection in cancers that break the rules of transplantation

Cancer Immunology, Immunotherapy

Volumn 59, Issue 5, 2010, Pages 643-651

  Fassati, Ariberto ^a   Mitchison, N Avrion ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Epigenetic; Immune selection; Occult tumour; Tasmanian devils; Transmissible

Indexed keywords

CANCER CELL; CANCER TRANSPLANTATION; CELL DEDIFFERENTIATION; CELL METABOLISM; CELL PROLIFERATION; DOG; IMMUNOGENICITY; IMMUNOSELECTION; IMMUNOSURVEILLANCE; MARSUPIAL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARCOPHILUS HARRISII; THEORY; TRANSMISSIBLE CANCER; TUMOR IMMUNITY; TUMOR REJECTION; ANIMAL; HUMAN; IMMUNOLOGY; TUMOR ESCAPE;

HISTOCOMPATIBILITY ANTIGEN;

ANIMALS; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNOLOGIC SURVEILLANCE; NEOPLASM TRANSPLANTATION; NEOPLASMS; TUMOR ESCAPE;

EID: 77950504048     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0809-1     Document Type: Review

References (83)

1. Mitchison N (1956) Antigens of heterozygous tumours as materials for the study of cell heredity. Proc Roy Phys Soc 25:45-48
2. Klein E, Klein G, Revesz L (1957) Permanent modification (mutation?) of a histocompatibility gene in a heterozygous tumor. J Natl Cancer Inst 19:95-114
3. Koebel CM et al (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903-907
4. Murgia C et al (2006) Clonal origin and evolution of a transmissible cancer. Cell 126:477-487 (Pubitemid 44163607)
5. Thornley M (2004) Devils advocates Tasmanian. Devil facial tumor project. Aust Vet J 82:584
6. Siddle HV et al (2007) Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. Proc Natl Acad Sci USA 104:16221-16226
7. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137-148
8. Cabrera T et al (2007) HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 56:709-717 (Pubitemid 46348739)
9. Choudhury SR, Knapp LA (2001) Human reproductive failure II: immunogenetic and interacting factors. Hum. Reprod Update 7:135-160 (Pubitemid 32208495)
10. Tian L, Catt JW, O'Neill C, King NJ (1997) Expression of immunoglobulin superfamily cell adhesion molecules on murine embryonic stem cells. Biol Reprod 57:561-568 (Pubitemid 27349916)
11. Hori J et al (2003) Neural progenitor cells lack immunogenicity and resist destruction as allografts. Stem Cells 21:405-416 (Pubitemid 36798086)
12. Mammolenti M, Gajavelli S, Tsoulfas P, Levy R (2004) Absence of major histocompatibility complex class I on neural stem cells does not permit natural killer cell killing and prevents recognition by alloreactive cytotoxic T lymphocytes in vitro. Stem Cells 22:1101-1110 (Pubitemid 39507095)
13. Snell GD (1953) The genetics of transplantation, J Natl Cancer Inst 14:691-700 (discussion 701-4)
14. Jimenez P et al (1999) Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 83:91-97 (Pubitemid 29409483)
15. Yauk CL, Bois PR, Jeffreys AJ (2003) High-resolution sperm typing of meiotic recombination in the mouse MHC Ebeta gene. EMBO J 22:1389-1397
16. Garcia-Lora A et al (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 106:521-527 (Pubitemid 36966208)
17. Novinski M (1876) Zur Frage uber die impfung der krebsigen geschwulste. Zentralb Med Wissensch 14:790-791
18. Cohen D (1985) The canine transmissible venereal tumor: a unique result of tumor progression. Adv Cancer Res 43:75-112
19. Rebbeck CA et al (2009) Origins and evolution of a transmissible cancer. Evolution 63:2340-2349
20. Cohen D (1973) The biological behaviour of the transmissible venereal tumour in immunosuppressed dogs. Eur J Cancer 9:253-258
21. Perez J, Day MJ, Mozos E (1998) Immunohistochemical study of the local inflammatory infiltrate in spontaneous canine transmissible venereal tumour at different stages of growth. Vet Immunol Immunopathol 64:133-147 (Pubitemid 28300277)
22. Gonzalez CM et al (2000) Canine transmissible venereal tumour: a morphological and immunohistochemical study of 11 tumours in growth phase and during regression after chemotherapy. J Comp Pathol 122:241-248
23. McCallum H (2008) Tasmanian devil facial tumour disease: lessons for conservation biology. Trends Ecol Evol 23:631-637
24. Pearse AM, Swift K (2006) Allograft theory: transmission of devil facial-tumour disease. Nature 439:549
25. Siddle HV, Sanderson C, Belov K (2007) Characterization of major histocompatibility complex class I and class II genes from the Tasmanian devil (Sarcophilus harrisii), Immunogenetics 59:753-760 (Pubitemid 47415564)
26. Akagi T et al (2009) Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma. Int J Cancer 125:2349-2359
27. Rodriguez T et al (2005) High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. Cancer Immunol Immunother 54:141-148 (Pubitemid 40100836)
28. Mendez R et al (2008) Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol Immunother 57:719-729 (Pubitemid 351641032)
29. Masuda K et al (2007) Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts. Cancer Sci 98:102-108 (Pubitemid 44803927)
30. Isoda T et al (2009) Immunologically silent cancer clone transmission from mother to offspring. Proc Natl Acad Sei USA 106:17882-17885
31. Bleakley M, Lau L, Shaw PJ, Kaufman A (2002) Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis. Bone Marrow Transplant 29:843-852 (Pubitemid 34679230)
32. Vago L et al (2009) Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 361:478-488
33. Cohen D, Shalev A, Krup M (1984) Lack of beta 2-microglobulin on the surface of canine transmissible venereal tumor cells. J Natl Cancer Inst 72:395-401 (Pubitemid 14198863)
34. Yang TJ, Chandler JP, Dunne-Anway S (1987) Growth stage dependent expression of MHC antigens on the canine transmissible venereal sarcoma. Br J Cancer 55:131-134
35. Yang TJ (1988) Immunobiology of a spontaneously regressive tumor, the canine transmissible venereal sarcoma (review). Anticancer Res 8:93-95
36. Gerloni M, Zanetti M (2005) CD4 T cells in tumor immunity. Springer Semin Immunopathol 27:37-48
37. Depontieu FR et al (2009) Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci USA 106:12073-12078
38. Cohen D (1972) Detection of humoral antibody to the transmissible venereal tumour of the dog. Int J Cancer 10:207-212
39. Reith W, Mach B (2001) The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 19:331-373 (Pubitemid 32368039)
40. Muller-Hilke B, Mitchison NA (2006) The role of HLA promoters in autoimmunity. Curr Pharm Des 12:3743-3752
41. Mitchison NA, Mayer W (2007) A survey of H2 gene sequences, including new wild-derived genes. Int J Immunogenet 34:3-12
42. Wright KL, Ting JP (2006) Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 27:405-412 (Pubitemid 44216195)
43. Chang YC et al (2008) Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood 111:5054-5063
44. Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27:5869-5885
45. Setiadi AF et al (2008) Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res 68:9601-9607
46. Yip L et al (2009) Deaf 1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. Nat Immunol 10:1026-1033
47. Malmberg KJ et al (2008) NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol Immunother 57:1541-1552
48. Ambrosino E, Berzofsky JA, Terabe M (2008) Regulation of tumor immunity: the role of NKT cells. Expert Opin Biol Ther 8:725-734 (Pubitemid 351860202)
49. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N (2008) HLA-G: from biology to clinical benefits. Trends Immunol 29:125-132
50. Lin CY et al (2008) Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity. Cancer Lett 272:285-295
51. Kang SM, Tang Q, Bluestone JA (2007) CD4+ CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant 7:1457-1463 (Pubitemid 46776267)
52. Scheffold A, Huhn J, Hofer T (2005) Regulation of CD4+ CD25+ regulatory T cell activity: it takes (IL-)two to tango. Eur J Immunol 35:1336-1341 (Pubitemid 40691414)
53. Mozos E et al (1996) Immunohistochemical characterization of canine transmissible venereal tumor. Vet Pathol 33:257-263 (Pubitemid 126481503)
54. Marchai T et al (1997) Immunophenotype of the canine transmissible venereal tumour. Vet Immunol Immunopathol 57:1-11
55. Hsiao YW, Liao KW, Hung SW, Chu RM (2004) Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. J Immunol 172:1508-1514
56. Dunn GP et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998
57. Chou PC et al (2009) Effects of immunotherapy of IL-6 and IL15 plasmids on transmissible venereal tumor in beagles. Vet Immunol Immunopathol 130:25-34
58. Scherer MN et al (2007) Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg 392:511-523 (Pubitemid 47246715)
59. Geissler EK, Schlitt HJ (2009) Immunosuppression for liver transplantation. Gut 58:452-463
60. Uppaluri R, Dunn GP, Lewis JS Jr (2008) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun 8:1.6
61. Milne K et al (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA1 as positive prognostic factors. PLoS One 4:e6412
62. Galon J et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964 (Pubitemid 44498003)
63. Pierobon M et al (2009) Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2EGFR signaling activation as a potential prognostic pathway biomarker. Clin Colorectal Cancer 8:110-117
64. Hsiao YW, Liao KW, Hung SW, Chu RM (2002) Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells. Vet Immunol Immunopathol 87:19-27 (Pubitemid 34621428)
65. Willimsky G, Blankenstein T (2005) Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437:141-146 (Pubitemid 41613441)
66. Shackleton M, Quintana E, Fearon ER, Morrison SJ (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138:822-829
67. Chang CC, Ferrone S (2007) Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56:227-236
68. Méndez R et al (2009) HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunol Immunother 58:1507-1515
69. Mehling M et al (2007) WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol 114:111-119
70. Carosella ED, HoWangYin KY, Favier B, LeMaoult J (2008) HLA-G-dependent suppressor cells: Diverse by nature, function, and significance. Hum Immunol 69:700-707
71. Kretschmer K, Apostolou I, Verginis P, von Boehmer H (2008) Regulatory T cells and antigen-specific tolerance. Chem Immunol Allergy 94:8-15
72. Comin-Anduix B et al (2008) Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transi Med 6:22 (Pubitemid 351803824)
73. Kavanagh B et al (2008) CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dosedependent fashion. Blood 112:1175-1183
74. Kryczek I et al (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114:1141-1149
75. Verheyden S et al (2009) Role of the inhibitory KIR ligand HLABw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells. Cancer Immunol Immunother 58:855-865
76. Schwinn N et al (2009) Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer 124:1594-1604
77. Cheever MA (2008) Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222:357-368
78. Moutsopoulos NM, Wen J, Wahl SM (2008) TGF-beta and tumors - an ill-fated alliance. Curr Opin Immunol 20:234-240
79. Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836-848
80. Lob S, Konigsrainer A (2008) Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction? Langenbecks Arch Surg 393:995-1003
81. Ikeda H, Old LJ, Schreiber RD (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95-109 (Pubitemid 34229385)
82. Wajant H (2006) CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat Res 130:141-165
83. Zhou J et al (2009) Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 113:4052-4062